

# LAIV

## Health Care Provider Updates for 2023-24

### What Providers Need to Know for the 2023-2024 Influenza Season

The Centers for Disease Control and Prevention (CDC) continue to recommend annual flu vaccination for everyone aged 6 months and older. The Advisory Committee on Immunization Practices (ACIP) recommends that live attenuated influenza vaccine (LAIV4, FluMist®) be an option for flu vaccination of persons for whom it is appropriate for the 2023-24 season (**i.e., healthy, non-pregnant persons aged 2 through 49 years**).

### Key Facts

- All nasal spray influenza vaccines for the 2023-24 flu season are quadrivalent, meaning they are designed to protect against four flu viruses: an influenza A(H1N1) virus, an influenza A(H3N2) virus, and two influenza B viruses.
- ACIP will continue to review data concerning the effectiveness of LAIV4 as they become available. This is an example of scientific research influencing policies to improve overall population health.
- ACIP does not indicate a preference for one vaccine product over another for persons aged 6 months through 64 years whom more than one vaccine product is licensed, recommended and appropriate.
- The American Academy of Pediatrics (AAP), in their formal policy statement, recommends children receive either injectable (inactivated) flu vaccine or LAIV4 for the 2023-24 influenza season.
- For more information about LAIV4 recommendations visit:  
[www.cdc.gov/flu/prevent/nasalspray.htm](http://www.cdc.gov/flu/prevent/nasalspray.htm)

### Provider Information

- The Flu Vaccine Information Statements (VIS) for IIV/RIV and LAIV were updated on 8/6/21. To access them, go to [www.michigan.gov/immunize](http://www.michigan.gov/immunize) → Health Care Professionals/Providers → Vaccine Information Statements (VIS) is at the top.
- LAIV4 will be available under the Vaccines for Children program for the 2023-24 season.
- Flu vaccine handouts for the 2023-24 season can be found at [www.michigan.gov/flu](http://www.michigan.gov/flu) → Resources tab → Resources for Health Professionals

For more information, refer to: "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the ACIP—U.S., 2023-24 Influenza Season," MMWR Recomm Rep 2023; 72(2);1–25, located at [www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm?s\\_cid=rr7202a1\\_w](http://www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm?s_cid=rr7202a1_w) ; LAIV prescribing information [www.fda.gov/vaccines-blood-biologics/vaccines/flumist-quadrivalent](http://www.fda.gov/vaccines-blood-biologics/vaccines/flumist-quadrivalent) and American Academy of Pediatrics at <https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2023-063772/193776/Recommendations-for-Prevention-and-Control-of>